M. T. Ravi Subbiah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
M. T. Ravi Subbiah has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
W. Abplanalp
Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, OH 45219 USA
1 shared publicationWilliam Abplanalp
1 shared publication
Latest Publications
- 1 December 2008
- Published by SAGE Publications in OMICS: A Journal of Integrative Biology
- Vol. 12 (4) , 229-235
Understanding the Nutrigenomic Definitions and Concepts at the Food–Genome Junction
The marked differences in individual response to dietary factors have led to major controversies in nutrition and puzzled nutrition scientists over the last century. The emerging field of nutrigenomics helps us to understand the basis for some of these differences and also promises us the ability to tailor diet based on individual genetic makeup. Great advances in Human Genome Project, documentation of single nucleotide polymorphisms (SNPs) in candidate genes and their association with metabolic imbalances have gradually added new tests to the nutrigenomic panel. Studies based on ethnopharmacology and phytotherapy concepts showed that nutrients and botanicals can interact with the genome causing marked changes in gene expression. This has led to the commercial development of nutraceuticals and functional foods that can modify negative health effects of individual genetic profile bringing the field to the “food/genome” junction. Despite the promise of nutrigenomics to personalize diet, there is skepticism whether it can truly bring about meaningful modification of the risk factors connected to chronic diseases, due to the lack of large scale nutrition intervention studies. Several intervention studies currently underway in the United States and abroad (Israel, Spain, and France) will further help validate nutrigenomic concepts. France has already introduced a National Nutrition and Health Program to assess nutritional status and risk of major metabolic diseases. As the field(s) related to nutritional genomics advance in their scope, it is essential that: (a) strict guidelines be followed in the nomenclature and definition of the subdisciplines; and (b) the state/federal regulatory guidelines be updated for diagnostic laboratories, especially for those offering tests directly to the public (without a physician's request) to help protect the consumer.
- 1 December 2008
- Published by SAGE Publications in OMICS: A Journal of Integrative Biology
- Vol. 12 (4) , 229-235
Understanding the Nutrigenomic Definitions and Concepts at the Food–Genome Junction
The marked differences in individual response to dietary factors have led to major controversies in nutrition and puzzled nutrition scientists over the last century. The emerging field of nutrigenomics helps us to understand the basis for some of these differences and also promises us the ability to tailor diet based on individual genetic makeup. Great advances in Human Genome Project, documentation of single nucleotide polymorphisms (SNPs) in candidate genes and their association with metabolic imbalances have gradually added new tests to the nutrigenomic panel. Studies based on ethnopharmacology and phytotherapy concepts showed that nutrients and botanicals can interact with the genome causing marked changes in gene expression. This has led to the commercial development of nutraceuticals and functional foods that can modify negative health effects of individual genetic profile bringing the field to the “food/genome” junction. Despite the promise of nutrigenomics to personalize diet, there is skepticism whether it can truly bring about meaningful modification of the risk factors connected to chronic diseases, due to the lack of large scale nutrition intervention studies. Several intervention studies currently underway in the United States and abroad (Israel, Spain, and France) will further help validate nutrigenomic concepts. France has already introduced a National Nutrition and Health Program to assess nutritional status and risk of major metabolic diseases. As the field(s) related to nutritional genomics advance in their scope, it is essential that: (a) strict guidelines be followed in the nomenclature and definition of the subdisciplines; and (b) the state/federal regulatory guidelines be updated for diagnostic laboratories, especially for those offering tests directly to the public (without a physician's request) to help protect the consumer.
- 22 August 2007
- Published by Taylor & Francis in Personalized Medicine
- Vol. 4 (3) , 233-236
Personalizing Our Diet to Improve Our Health: The Potential Impact of Nutrigenomics
- 22 August 2007
- Published by Taylor & Francis in Personalized Medicine
- Vol. 4 (3) , 233-236
Personalizing Our Diet to Improve Our Health: The Potential Impact of Nutrigenomics
- 1 February 2007
- Published by Elsevier in Translational Research
- Vol. 149 (2) , 55-61
Nutrigenetics and nutraceuticals: the next wave riding on personalized medicine
- 1 February 2007
- Published by Elsevier in Translational Research
- Vol. 149 (2) , 55-61
Nutrigenetics and nutraceuticals: the next wave riding on personalized medicine
- 1 April 2004
- Published by Elsevier in Atherosclerosis
- Vol. 173 (2) , 371-372
Cardiovascular risk associated with hormone replacement therapy: some critical questions about the type of estrogen used in most clinical trials
- 1 April 2004
- Published by Elsevier in Atherosclerosis
- Vol. 173 (2) , 371-372
Cardiovascular risk associated with hormone replacement therapy: some critical questions about the type of estrogen used in most clinical trials
- Open Access
- 1 January 2003
- Published by Elsevier in The Lancet
- Vol. 361 (9353) , 255
Long-term effects of hormone replacement therapy
- 1 January 2003
- Published by Elsevier in The Lancet
- Vol. 361 (9353) , 255
Open AccessLong-term effects of hormone replacement therapy
- 1 January 2003
- Published by IMR Press in International Journal for Vitamin and Nutrition Research
- Vol. 73 (1) , 19-23
Ergosterol (Major Sterol of Baker’s and Brewer’s Yeast Extracts) Inhibits the Growth of Human Breast Cancer Cells in vitro and the Potential Role of its Oxidation Products
The derivation of chemopreventive agents from dietary sources has been the subject of considerable attention in recent years. Yeast extracts have been used as nutritional supplements for a number of years. In this communication we show that ergosterol (a 28-carbon sterol found in baker’s and brewer’s yeast) can prevent growth of breast cancer cells in vitro in the presence of estradiol-17beta. Estrogen receptor (+) MCF-7 cells appear to be more sensitive to ergosterol than estrogen receptor (–) MDA-231 cells. However, MDA-231 cells were more sensitive to ergosterol in terms of apoptotic effects than MCF-7 cells, indicating that other mechanisms (antiestrogenic activity) may also be operative in estrogen receptor (+) cells. Compared to freshly prepared ergosterol, stored preparations were more potent in inhibiting growth of cancer cells, indicating that oxidation product(s) of ergosterol may be responsible for the noted effects. Further studies on in vivo effects of ergosterol and lipid extracts of yeast in animal models are warranted to determine their potential for use as supplements in humans.
- 1 January 2003
- Published by IMR Press in International Journal for Vitamin and Nutrition Research
- Vol. 73 (1) , 19-23
Ergosterol (Major Sterol of Baker’s and Brewer’s Yeast Extracts) Inhibits the Growth of Human Breast Cancer Cells in vitro and the Potential Role of its Oxidation Products
The derivation of chemopreventive agents from dietary sources has been the subject of considerable attention in recent years. Yeast extracts have been used as nutritional supplements for a number of years. In this communication we show that ergosterol (a 28-carbon sterol found in baker’s and brewer’s yeast) can prevent growth of breast cancer cells in vitro in the presence of estradiol-17beta. Estrogen receptor (+) MCF-7 cells appear to be more sensitive to ergosterol than estrogen receptor (–) MDA-231 cells. However, MDA-231 cells were more sensitive to ergosterol in terms of apoptotic effects than MCF-7 cells, indicating that other mechanisms (antiestrogenic activity) may also be operative in estrogen receptor (+) cells. Compared to freshly prepared ergosterol, stored preparations were more potent in inhibiting growth of cancer cells, indicating that oxidation product(s) of ergosterol may be responsible for the noted effects. Further studies on in vivo effects of ergosterol and lipid extracts of yeast in animal models are warranted to determine their potential for use as supplements in humans.
- Open Access
- 1 March 2002
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 35 (3) , 271-276
Estrogen replacement therapy and cardioprotection: mechanisms and controversies
Epidemiological and case-controlled studies suggest that estrogen replacement therapy might be beneficial in terms of primary prevention of coronary heart disease (CHD). This beneficial effect of estrogens was initially considered to be due to the reduction of low density lipoproteins (LDL) and to increases in high density lipoproteins (HDL). Recent studies have shown that estrogens protect against oxidative stress and decrease LDL oxidation. Estrogens have direct effects on the arterial tissue and modulate vascular reactivity through nitric oxide and prostaglandin synthesis. While many of the effects of estrogen on vascular tissue are believed to be mediated by estrogen receptors alpha and ß, there is evidence for `immediate non-genomic' effects. The role of HDL in interacting with 17ß-estradiol including its esterification and transfer of esterified estrogens to LDL is beginning to be elucidated. Despite the suggested positive effects of estrogens, two recent placebo-controlled clinical trials in women with CHD did not detect any beneficial effects on overall coronary events with estrogen therapy. In fact, there was an increase in CHD events in some women. Mutations in thrombogenic genes (factor V Leiden, prothrombin mutation, etc.) in a subset of women may play a role in this unexpected finding. Thus, the cardioprotective effect of estrogens appears to be more complicated than originally thought and requires more research.
- 1 March 2002
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 35 (3) , 271-276
Open AccessEstrogen replacement therapy and cardioprotection: mechanisms and controversies
Epidemiological and case-controlled studies suggest that estrogen replacement therapy might be beneficial in terms of primary prevention of coronary heart disease (CHD). This beneficial effect of estrogens was initially considered to be due to the reduction of low density lipoproteins (LDL) and to increases in high density lipoproteins (HDL). Recent studies have shown that estrogens protect against oxidative stress and decrease LDL oxidation. Estrogens have direct effects on the arterial tissue and modulate vascular reactivity through nitric oxide and prostaglandin synthesis. While many of the effects of estrogen on vascular tissue are believed to be mediated by estrogen receptors alpha and ß, there is evidence for `immediate non-genomic' effects. The role of HDL in interacting with 17ß-estradiol including its esterification and transfer of esterified estrogens to LDL is beginning to be elucidated. Despite the suggested positive effects of estrogens, two recent placebo-controlled clinical trials in women with CHD did not detect any beneficial effects on overall coronary events with estrogen therapy. In fact, there was an increase in CHD events in some women. Mutations in thrombogenic genes (factor V Leiden, prothrombin mutation, etc.) in a subset of women may play a role in this unexpected finding. Thus, the cardioprotective effect of estrogens appears to be more complicated than originally thought and requires more research.